Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September, 2026, confirming the dematerialization of securities and updating the records of the company.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director of the company for a period of 5 years, effective from August 29, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the voting results of its 32nd Annual General Meeting (AGM), which was held on September 30, 2026. The meeting was conducted through video conferencing, and the voting results have been disclosed in accordance with Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resolutions passed include the adoption of the standalone financial statements for the financial year ended March 31, 2026, and the appointment of a new whole-time director.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the voting results and scrutinizer's report of its 32nd Annual General Meeting (AGM) held on September 30, 2026. The resolutions related to the standalone financial statements and the appointment of a director were passed with over 99% of votes in favor.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd held its 32nd Annual General Meeting (AGM) on September 30, 2026, through video conferencing. The meeting was attended by 73 members, and the company's financial statements for the year 2025-26 were adopted. The meeting also saw the appointment of a new director and the reappointment of another director.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the closure of its trading window for dealing in its securities, effective from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has submitted a newspaper publication for its 32nd Annual General Meeting and E-Voting information. Additionally, a notice of possession has been given by Punjab National Bank for an immovable property due to non-payment of a loan amount of Rs. 19,68,988.82. The company has also proposed to register M/s. KOKIFOOD & BEVERAGES LLP as a company limited by shares.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the availability of its Annual Report and Notice of Annual General Meeting for the financial year 2025-26 on its website. The report and notice are available for download from the website link provided. Shareholders are requested to update their email addresses and KYC details to receive future communications electronically.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced a notice of its Annual General Meeting (AGM) to be held on September 30, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has submitted its annual report for the financial year ended March 31, 2026, as per the regulatory requirement under Reg. 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed the BSE about the submission of an intimation of AGM date, scheduling the 32nd Annual General Meeting on September 30, 2026. The register of members and share transfer books will be closed from September 24 to September 30, 2026, for the purpose of the AGM. The remote e-voting period will begin on September 27 and end on September 29, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed the BSE about the appointment of Mr. Gnana Prakash Gattu as Whole-time Director of the company for a period of five years, effective from August 29, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the outcome of its board meeting, which was held on August 29, 2026. The board has approved the appointment of Gnana Prakash Gattu as a whole-time director of the company, effective from August 29, 2026. The company has also announced the date of its annual general meeting, which will be held on September 30, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 29/08/2026 to consider and approve Submission of Prior Intimation Of Board Meeting, including the 32nd Annual General Meeting, Board Report, appointment of Scrutinizer, and Whole Time Director.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has executed a 5-year land lease deed with Mr. Gnana Prakash Gattu for Micro Algae Cultivation and Glass Reactor Systems at Telangana, India.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has submitted its unaudited financial results for the quarter ended 30th June, 2026, showing a net profit of Rs. 352.48 crore and earnings per share of Rs. 2.32.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd submitted a statement of deviation and variation as per SEBI (Listing Obligation and Disclosure Requirements) 2015 for the quarter ended 30th June, 2026. The company has raised funds to meet long-term funding requirements, including working capital and general corporate purposes, to support its future growth plan.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced its unaudited standalone financial results for the quarter ended 30th June, 2026, with revenue from operations at Rs. 3,691.39 lakhs and total expenses at Rs. 3,579.98 lakhs, resulting in a profit from ordinary activities before exceptional items of Rs. 111.53 lakhs.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at Rs. 3,691.39 lakhs and total expenses at Rs. 3,579.98 lakhs.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/08/2026 to consider and approve the unaudited standalone financial results for the quarter ended on June 30, 2026.